Features of BAFF and APRIL Receptors on Circulating B Cells in Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2023 Feb 16

PMID 36794867

Authors

Yasuhiro Shimojima

Dai Kishida

Takanori Ichikawa

Ryota Takamatsu

Shun Nomura

Yoshiki Sekijima

Affiliations

Soon will be listed here.

Abstract

To investigate the features of circulating B cells, their expressing receptors, serum levels of B-cell activation factor of the TNF family (BAFF), and a proliferation-inducing ligand (APRIL) in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Blood samples from 24 patients with active AAV (a-AAV), 13 with inactive AAV (i-AAV), and 19 healthy controls (HC) were included in this study. The proportion of B cells and their expressing BAFF receptor (BAFF-R), transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), and B-cell maturation antigen were analyzed via flow cytometry. Serum levels of BAFF, APRIL, and interleukin (IL)-4, IL-6, IL-10, and IL-13 were also evaluated using an enzyme-linked immunosorbent assay. The proportion of plasmablasts (PB)/plasma cells (PC) and serum levels of BAFF, APRIL, IL-4, and IL-6 were significantly higher in a-AAV than in HC. Higher serum levels of BAFF, APRIL, and IL-4 were observed in i-AAV than in HC. Lower expression of BAFF-R on memory B cells and higher expression of TACI on CD19+ cells, immature B cells, and PB/PC were demonstrated in a-AAV and i-AAV than in HC. The population of memory B cells was positively associated with serum APRIL levels and BAFF-R expression in a-AAV. In conclusion, decreased expression of BAFF-R on memory B cells and increased expression of TACI on CD19+ cells, immature B cells, and PB/PC, as well as increased serum levels of BAFF and APRIL, were sustained even in the remission phase of AAV. Persistent aberrant signaling of BAFF/APRIL may contribute to disease relapse.

Citing Articles

Combination treatment with telitacicept, cyclophosphamide and glucocorticoids for severe Granulomatous polyangiitis: a case report and literature review.

Huang L, Lin W, Liu Y, Zhu J, Li Y, Zheng Z Front Immunol. 2023; 14:1298650.

PMID: 38106422 PMC: 10722187. DOI: 10.3389/fimmu.2023.1298650.

References

Schaper F, Rose-John S . Interleukin-6: Biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 2015; 26(5):475-87. DOI: 10.1016/j.cytogfr.2015.07.004. View

Carter R, Zhao H, Liu X, Pelletier M, Chatham W, Kimberly R . Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum. 2005; 52(12):3943-54. DOI: 10.1002/art.21489. View

Shimojima Y, Kishida D, Ichikawa T, Takamatsu R, Nomura S, Sekijima Y . Oxidative Stress Promotes Instability of Regulatory T Cells in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Front Immunol. 2021; 12:789740. PMC: 8691772. DOI: 10.3389/fimmu.2021.789740. View

Bossen C, Schneider P . BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 2006; 18(5):263-75. DOI: 10.1016/j.smim.2006.04.006. View

Prendecki M, McAdoo S . New Therapeutic Targets in Antineutrophil Cytoplasm Antibody-Associated Vasculitis. Arthritis Rheumatol. 2020; 73(3):361-370. DOI: 10.1002/art.41407. View

Charles P, Terrier B, Perrodeau E, Cohen P, Faguer S, Huart A . Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018; 77(8):1143-1149. DOI: 10.1136/annrheumdis-2017-212878. View

Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S . Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2008; 68(12):1827-32. DOI: 10.1136/ard.2008.101279. View

DallEra M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A . Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007; 56(12):4142-50. DOI: 10.1002/art.23047. View

Hunter C, Jones S . IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015; 16(5):448-57. DOI: 10.1038/ni.3153. View

10.

Warnatz K, Salzer U, Rizzi M, Fischer B, Gutenberger S, Bohm J . B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci U S A. 2009; 106(33):13945-50. PMC: 2722504. DOI: 10.1073/pnas.0903543106. View

11.

Rauch M, Tussiwand R, Bosco N, Rolink A . Crucial role for BAFF-BAFF-R signaling in the survival and maintenance of mature B cells. PLoS One. 2009; 4(5):e5456. PMC: 2673681. DOI: 10.1371/journal.pone.0005456. View

12.

Yan M, Wang H, Chan B, Roose-Girma M, Erickson S, Baker T . Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol. 2001; 2(7):638-43. DOI: 10.1038/89790. View

13.

Sellam J, Miceli-Richard C, Gottenberg J, Ittah M, Lavie F, Lacabaratz C . Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus. Ann Rheum Dis. 2006; 66(6):790-7. PMC: 1954659. DOI: 10.1136/ard.2006.065656. View

14.

Pollard R, Abdulahad W, Vissink A, Hamza N, Burgerhof J, Meijer J . Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial. Ann Rheum Dis. 2012; 72(1):146-8. DOI: 10.1136/annrheumdis-2012-202071. View

15.

Vincent F, Saulep-Easton D, Figgett W, Fairfax K, Mackay F . The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013; 24(3):203-15. PMC: 7108297. DOI: 10.1016/j.cytogfr.2013.04.003. View

16.

Matsumoto K, Suzuki K, Yoshimoto K, Seki N, Tsujimoto H, Chiba K . Significant association between clinical characteristics and immuno-phenotypes in patients with ANCA-associated vasculitis. Rheumatology (Oxford). 2019; 59(3):545-553. DOI: 10.1093/rheumatology/kez327. View

17.

Stohl W, Hiepe F, Latinis K, Thomas M, Scheinberg M, Clarke A . Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012; 64(7):2328-37. PMC: 3350827. DOI: 10.1002/art.34400. View

18.

Shimojima Y, Kishida D, Nomura S, Sekijima Y . Cerebrospinal fluid levels of BAFF and APRIL as direct indicators of disease activity in anti-neutrophil cytoplasmic antibody-related hypertrophic pachymeningitis. Clin Rheumatol. 2020; 39(10):3145-3148. DOI: 10.1007/s10067-020-05270-6. View

19.

Stadanlick J, Kaileh M, Karnell F, Scholz J, Miller J, Quinn 3rd W . Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. Nat Immunol. 2008; 9(12):1379-87. PMC: 2744141. DOI: 10.1038/ni.1666. View

20.

Seyler T, Park Y, Takemura S, Bram R, Kurtin P, Goronzy J . BLyS and APRIL in rheumatoid arthritis. J Clin Invest. 2005; 115(11):3083-92. PMC: 1257539. DOI: 10.1172/JCI25265. View